Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MenQuadfi + Hexaxim
- Development stage
- Unknown
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This combination refers to the concomitant administration of Sanofi Pasteur's quadrivalent meningococcal conjugate vaccine (MenACYW-TT, brand name MenQuadfi) and a hexavalent pediatric vaccine (DTaP-IPV-HepB-Hib, such as Hexaxim or Vaxelis). MenQuadfi is designed to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y by utilizing tetanus toxoid as a carrier protein for the capsular polysaccharides. The hexavalent component (Hexaxim/Hexyon) provides protection against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and Haemophilus influenzae type b. Clinical evaluation of these vaccines administered together (as seen in trial MET57) aims to simplify pediatric immunization schedules while maintaining safety and high immunogenicity for all ten targeted pathogens.
- Brand names
- MenQuadfiHexaximHexyonVaxelis
- Other names
- DTaP-IPV-HepB-Hib + MenACYW-TTMeningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine + Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b conjugate vaccine
02
Targets
PRNP (Cellular Prion Protein)NmA CPS (Neisseria meningitidis group A capsular polysaccharide)FHA (Filamentous hemagglutinin)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideHBsAg (Hepatitis B surface antigen)TT (Tetanus toxoid)MenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)
Beyond the preview
Go deeper on MenQuadfi + Hexaxim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MenQuadfi + Hexaxim.